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Abstract
Transforming growth factor-B1 (TGF-B1) can be tumor-
suppressive through the activation of the Smad-
mediated signaling pathway. TGF-B1 can also enhance
tumor progression by stimulating epithelial-to-
mesenchymal transition (EMT) through additional
pathways. EMT is characterized by the acquisition of
a fibroblast-like cell morphology, dissolution of
tight junctions, disruption of adherence junctions,
and formation of actin stress fibers. There is evidence
linking the activation of mitogen-activated protein
kinase pathways to the induction of TGF-B1–mediated
EMT. However, the role of Erk in the induction of
TGF-B1–mediated EMT remains unclear. TGF-B1 treat-
ment of normal murine mammary gland (NMuMG)
epithelial cells resulted in increased gene expression
of Ras, Raf, MEK1/2, and Erk1/2, as shown by micro-
array analysis and real-time polymerase chain reac-
tion. Upon 24 and 48 hours of treatment with TGF-B1,
NMuMG and mouse cortical tubule (MCT) epithelial
cells underwent EMT as shown by changes in cell
morphology, delocalization of zonula occludens-1 and
E-cadherin from cell–cell junctions, and formation of
actin stress fibers. TGF-B1 treatment also resulted
in increased levels of phosphorylated Erk and Erk
kinase activity. Treatment with an MEK inhibitor,
U0126, inhibited increased Erk phosphorylation and
kinase activity, and blocked TGF-B1–induced EMT in
both cell lines. These data show that TGF-B1 induces
the activation of the Erk signaling pathway, which is
required for TGF-B1–mediated EMT in vitro.
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Introduction
Transforming growth factor-b1 (TGF-b1) signaling con-
trols many cellular processes, including cell proliferation,
differentiation, apoptosis, and epithelial-to-mesenchymal
transition (EMT) [1]. TGF-b1 signals through cell surface
serine–threonine kinase type II (TbRII) and type I (TbRI)
receptors. TGF-b1 binding to TbRII triggers TbRI associa-
tion with TbRII. TbRII phosphorylates and activates TbRI,
which phosphorylates receptor-associated (RA) Smads
(Smad2 and Smad3). RA-Smads bind Smad4 and translo-
cate to the nucleus, where they regulate the transcription of tar-
get genes [2] . Smad-dependent signaling is required for the
antiproliferative activity of TGF-b1 [3], which mediates TGF-b1
tumor-suppressive effects in early stages of tumorigenesis.
However, Smad-independent TGF-b1 signaling has been dem-
onstrated, involving the mitogen-activated protein kinase
(MAPK) pathways, including Jun N-terminal kinase (JNK)
[4–6], extracellular signal–regulated kinase (Erk) [7], and p38
mitogen–activated protein kinase (p38MAPK) [8]. Phosphatidyl
inositol 3-kinase–Akt (PI3-Akt) and RhoA pathways were also
reported to be activated by TGF-b1 signaling [9,10]. These path-
ways may be more closely associated with TGF-b1 induction of
EMT and may promote tumor cell invasion and metastasis.
The differentiated epithelial phenotype is characterized by
structural and functional polarization of the cell surface, and
formation of a junctional complex that mediates strong inter-
cellular adhesion and polarity [11]. E-cadherin, the major
component of adherens junctions, forms homophilic contacts
between neighboring cells. Tight junctions consist of a multi-
protein complex, including the protein zonula occludens-1
(ZO-1), that link tight junctions to microfilaments [12]. EMT is
a complex process associated with the loss of this epithelial
cell phenotype, dissolution of the junctions containing ZO-1 and
E-cadherin, and reorganization of the actin cytoskeleton
[9,13,14]. TGF-b1 is a prominent EMT-inducing factor in both
normal and pathologic conditions, such as in development of
cancer. The induction of EMT by TGF-b1 is associated with
the activation of JNK, p38, Erk, PI3k–Akt, and RhoA. However,
the precise role of these pathways in the induction of EMT
by TGF-b1 is unclear.
Expression profiling analysis is a powerful tool to study the
regulation of multiple signaling pathways. Microarray has been
utilized to study TGF-b1–mediated EMT [15]; however, this
analysis has not been performed on mammary gland epithelial
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cells until our previous study [16]. In that study, expression
profiling was performed by microarray on mouse mammary
gland epithelial cells (NMuMG) that underwent EMT upon
treatment with TGF-b1. Interestingly, treatment of NMuMG
with TGF-b1 for 1, 6, and 24 hours resulted in increased
gene expression of Erk signaling pathway components,
including Ras, MEK1/2, and Erk1/2.
Based on the observation that the Erk signaling pathway
is activated in NMuMG in response to TGF-b1, we used real-
time polymerase chain reaction (RT-PCR) in our current
study to confirm the microarray data. Furthermore, the role
of the Erk signaling pathway in TGF-b1–induced EMT was
investigated using the MEK inhibitor, U0126, in NMuMG
cells. Although there is growing interest in TGF-b1–mediat-
ed EMT, this is a rare event in vitro. To identify alternative
cell systems in which to study TGF-b1–induced EMT, 18
established human and mouse cell lines were screened for
TGF-b1–induced EMT. Of the cell lines screened, only two
underwent TGF-b1– induced EMT: NMuMG and MCT
(mouse proximal tubule epithelial cells) [38]. Tubulointersti-
tial fibrosis is a common end-point of many chronic renal
diseases and contributes to the permanent loss of renal
function. There is increasing evidence that TGF-b1 plays an
essential role in this profibrogenic process. So the role of
the Erk signaling pathway in TGF-b1– induced EMT was
also investigated in this relevant cell model of MCT. Our data
showed that the Erk pathway was required for TGF-b1–
induced EMT in NMuMG andMCT, as indicated by the block-
age of TGF-b1–induced EMT in both cell lines by U0126.
Materials and Methods
Antibodies and Other Reagents
Porcine TGF-b1 was from R&D System (Minneapolis,
MN), prepared in 10 mg/ml stocks in 4 mM HCl. The
MEK1/2 inhibitor U0126 (Promega, Madison, WI) was kept
as 10 mM stocks in DMSO according to manufacturer’s
instructions. Antibodies used for immunofluorescence were
ZO-1 (Zymed, South San Francisco, CA) and E-cadherin
(Transduction Laboratories, Lexington, KY). Texas Red-X
phalloidin and Hoechst 33258 were from Molecular Probes
(Eugene, OR). The biotin-conjugated secondary antibodies
were from Vectastain Elite ABC kits (Vectastain, Burlingame,
CA). Streptavidin-conjugated Cy3was fromSigma (St. Louis,
MO). The following antibodies were used for Western blot
analysis: phospho-Smad2 (Upstate Biotechnology Inc., Lake
Placid, NY); total Smad2/3 (Transduction Laboratories);
phospho-Raf1, total Raf1, phospho-MEK1/2, total MEK1/2,
phospho-Erk, and total Erk (Cell Signalling Technology,
Beverly, MA); and b1-actin (Santa Cruz Biotechnology, Santa
Cruz, CA). Secondary horseradish peroxidase–conjugated
anti–mouse and anti–rabbit antibodies were purchased from
Dako (Carpinteria, CA). ECL Western Blotting Detection
Reagents were purchased from Amersham Biosciences
(Piscataway, NJ). The Erk1 (C-16) rabbit polyclonal antibody
(Santa Cruz Biotechnology) was used for kinase assays.
Cell Culture and Treatment
NMuMG cells were grown in 10% FBS–Dulbecco’s mod-
ified Eagle’s medium (DMEM) containing 10 mg/ml insulin.
MCT cells were grown in 10% FBS–DMEM. Cells were
cultured in a humidified atmosphere (5% CO2) at 37jC until
they were 70–80% confluent. All cell culture reagents were
from Hyclone (Logan, UT). For each experiment, cells were
treated with TGF-b1 (4 ng/ml), TGF-b1 (4 ng/ml) plus U0126
(10 mm), or 10 mm U0126 alone, or left untreated. The
treatment times were either 24 or 48 hours depending
on the particular assay. Each experiment was conducted at
least three times.
Microarray and RT-PCR
Microarray and data analyses were described previously
[16]. To verify the data obtained from microarrays, RT-PCR
analysis of selected genes was performed. The follow-
ing primers were designed with primer express soft-
ware (Applied Biosystems, Foster City, CA) and used for
RT-PCR: H-ras (forward) GCAATTTATGCTGCCGAAT-
CTC; H-ras (reverse) CAGCTATGGCATCCCCTACATT;
N-ras (forward) AGCAGTGACGATGGCACTCAA; N-ras
(reverse) GGCATCAGTGCAGCTTCAAAGT; Raf1 (for-
ward) GAAAGCCATCCACACAGGACA; Raf1 (reverse)
TGCCAGTTTTGCACATGGAG; MEK2 (forward) TTGAT-
GAAGGCGTGGTTCATC; MEK2 (reverse) CCAGTGGTGT-
GTTCAGCTCAGA; Erk1 (forward) GCGTTACATGTGG-
CAGCTTGA; Erk1 (reverse) TGGAACCCCACCCCATTTT;
b1-actin (forward) AGAAAATCTGGCACCACACC; and
b1-actin (reverse) GGGGTGTTGAAGGTCTCAAA.
Primers were designed to have similar GC content and
melting temperatures. In general, amplicons were between
100 and 150 nucleotides in length. Thermal cycling was
performed using an ABI Prism 7700 Sequence Detector
(Perkin-Elmer Applied Biosystems, Foster, CA). Data anal-
ysis was performed with a Sequence Detector, version 1.7.
Total RNA (5 mg) was reverse-transcribed with random
primers using the Super Script II (Invitrogen, Carlsbad, CA)
according to the recommendations of the manufacturer. To
minimize variation, all RNA samples from a single experi-
ment were reverse-transcribed simultaneously. Reactions
contained 1 Sybergreen Universal PCR Master Mix,
150 nM forward and reverse primers, and 1 ml of cDNA in a
50 ml reaction volume. Thermal cycling was performed using
40 cycles at 95jC for 15 seconds and 60jC for 1 minute.
Amplicon size and reaction specificity were confirmed by
1.5% agarose gel electrophoresis. Each PCR was repeated
three times with RNA samples isolated from three indepen-
dent experiments, and the average median threshold cycle
values were used for analysis. b1-Actin was used to normal-
ize samples for comparison. Comparative CT method was
used, where the fold change was calculated by the arithme-
tic formula: 200CT.
Immunofluorescence
NMuMG and MCT cells were grown on glass coverslips
(22  22 mm). At 80% confluency, NMuMG and MCT cells
were treated with TGF-b1 and/or U0126 for 24 and 48 hours,
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respectively, as described in the Materials and Methods
section. After treatment, cells were washed three times with
phosphate-buffered saline (PBS) and fixed. For ZO-1 and
E-cadherin staining, cells were fixed with ice-cold methanol
for 20 minutes; for F-actin staining, cells were fixed at room
temperature (RT) with 4% paraformaldehyde in PBS and
then permeabilized with 0.05% Triton X-100 for 10 minutes.
Cells were washed three times in PBS after each antibody
incubation hereafter. Cells were blocked with 3% nonfat dry
milk in PBS for 60 minutes at RT, incubated for 60 minutes
with primary antibodies diluted in 3% milk/PBS, incubated
with biotinylated secondary antibodies for 1 hour at RT, and
incubated with streptavidin-conjugated Cy3 for 1 hour at RT.
F-actin was stained with Texas Red-X phalloidin (2 U/ml) for
20 minutes at RT after permeabilization. Cell nuclei were
stained with 1 mg/ml Hoechst 33258 for 10 minutes at RT.
Coverslips were mounted on 25  75 mm microslides (VWR
Scientific, Bridgeport, NJ) using AquaPolyMount (Polyscien-
ces, Warrington, PA). Cell morphology was monitored and
photographed using an inverted phase contrast microscope
(Olympus CK40; Olympus American Inc., Melville, NY).
Fluorescent images were captured using a Princeton Instru-
ments cooled CCD digital camera (Princeton Scientific
Instruments Inc., Mammouth Junction, NJ) from a Zeiss
Axiophot upright microscope (Carl Zeiss, Jena, Germany).
Images were processed using Image Pro Plus software
(Media Cybernetics, Silver Spring, MD).
Immunoblot Analysis
Cells were incubated in serum-free medium for 24 hours
and treated with TGF-b1 and/or U0126 in serum-free medi-
um as described in the Cell Culture and Treatment section.
Cells were lysed in buffer containing 50 mM HEPES pH 7.5,
150 mM NaCl, 0.2 mM sodium vanadate, 10% glycerol, 1%
NP-40, 0.1% SDS, 5 mM PNPP ( p-nitrophenyl phosphate di
Tris salt), 5 mM b-glycerol phosphate, 5 mM EDTA, 1 mM
EGTA, 10 nM microcystine, and 200 mM phenylmethylsul-
fonyl fluoride (PMSF). Tris buffered saline with Tween 20
(TBST) was TBS-supplemented with 0.2% Tween 20. TBS
buffer contained 100 mM Tris–HCl pH 7.5 and 0.9% NaCl.
Protein concentrations in cell lysates were determined by the
Bradford method. Protein extracts (40 mg/lane) were sepa-
rated by 10% SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membranes (100 V,
70 minutes). Membranes were blocked with 5% BSA in
TBST for 1 hour at RT and then incubated with primary
antibodies in 5% BSA in TBST for 2 hours at RT, followed by
incubation with secondary antibodies for 1 hour at RT.
Membranes were washed five times in TBST and immuno-
reactive bands were detected by enhanced chemilumines-
cence (ECL; Amersham Biosciences). Molecular weights
were estimated by comparison with BenchMark Prestained
Protein Ladder (Invitrogen).
Kinase Assays
Kinase assays to detect Erk1 activity were performed on
NMuMGandMCT cells treated with TGF-b1 and/or U0126 as
described in the Cell Culture and Treatment section. Protein
extractions and determination of protein concentrations
were described above. Soluble lysates (500 mg of protein)
were incubated with 1.5 mg of Erk1 antibody with gentle
rocking overnight at 4jC. As a negative control, nontreated
cell lysates were incubated with 1.5 mg of rabbit IgG. Protein
G Sepharose (30 ml) was added to each immunoprecipita-
tion complex, and incubated at 4jC for 3 hours while
gently rocking. Then the immune complexes were washed
three times with lysis buffer, two times with kinase buffer
(25 mmol/l Tris pH 7.5, 5 mmol/l b1-glycerolphosphate,
2 mmol/l dithiothreitol, 0.1 mmol/l Na3VO4, and 10 mmol/l
MgCl2), and resuspended in 40 ml of kinase buffer contain-
ing 5 mmol of ATP, 5 mCi of 32P ATP, and 5 mg of myelin basic
protein. The kinase reactions were initiated by incubation
at 37jC for 30 minutes. After boiling for 5 minutes, samples
were subjected to 12% SDS-PAGE (20 ml in each lane). The
intensity of the identified bands was detected using a
Fujifilm FLA-5000 phosphoimager (Fuji Photo Film Co. Ltd.,
Stamford, CT). Equal amounts of the samples were sub-
jected to 12% SDS-PAGE and analyzed by immunoblotting
with Erk1 antibodies to detect total Erk1.
Results
TGF-b1 Induced the Erk Signaling Pathway in NMuMG
Microarray analyses were performed on RNA from
NMuMG cells treated with TGF-b1 for 1, 6, and 24 hours,
Table 1. Microarray Analysis of TGF-h1–Treated NMuMG Cells Shows
Upregulation of Genes in the Erk Pathway.
Gene name TGF-b1 treatment
1 hour 6 hours 24 hours
H-ras 1.39 1.57 2.50
N-ras 2.25 1.34 2.14
Raf1 0.84 1.66 1.47
MEK2 1.98 2.14 1.65
Erk1 1.73 3.22 2.22
The values shown are RNA expression ratios of cells treated and not treated
with TGF-h1 (4 ng/ml) for 1, 6, or 24 hours, after background deduction and
normalization. Values greater than 2.0 are indicative of an above two-fold
upregulation of gene expression. Data were analyzed according to Xie et al. [16].
Table 2. Comparison of TGF-h1– Induced Gene Expression Fold Changes
from Microarray Analysis and RT-PCR in NMuMG cells.
Genes TGF-h1 (hours) Microarray RT-PCR
H-ras 24 2.5 No change
N-ras 1 2.25 2.48
24 2.14 2.71
Raf1 1 No change 2.51
MEK2 6 2.14 2.52
Erk1 6 3.22 2.88
24 2.22 2.34
The microarray values are taken from Table 1. Values greater than 2.0 are
indicative of an over two-fold upregulation of gene expression. Values less
than 2.0 are not shown. RT-PCR values are shown as fold change between
TGF-h1– treated and nontreated cells. Each RT-PCR analysis was repeated
three times with RNA samples isolated from three independent experiments
and the average median threshold cycle values were used for comparison.
b1-Actin was used to normalize RNA levels between samples.
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Figure 1. Inhibition of TGF-1–mediated EMT by the MEK inhibitor, U0126. NMuMG and MCT cells were treated with 4 ng/ml TGF-1 in the absence or presence
of 10 M U0126 for 24 hours (NMuMG) or 48 hours (MCT). Nontreated cells or cells treated with U0126 alone were used as negative controls. Phase contrast
images (200) were captured to analyze cell morphology. Cells were stained for ZO-1, E-cadherin, and F-actin (red) and were counterstained with Hoechst 33258
(blue) to visualize cell nuclei. Immunofluorescent images were captured at 400 magnification. Upon TGF-1 treatment, cells elongated, ZO-1 and E-cadherin
disappeared from cell junctions, and F-actin stress fibers formed. The MEK inhibitor (U0126) blocked these effects induced by TGF-1.
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using a National Institute of Aging 15k cDNA set. Table 1
illustrates the expression levels of genes related to the Erk
pathway upon treatment with TGF-b1 for 1, 6, and 24 hours.
Values greater than 2.0 were indicative of an above two-fold
upregulation of gene expression. Values less than 2.0 were
not considered significant. H-ras (24 hours), N-ras (1 and 24
hours), MEK2 (6 hours), and Erk1 (6 and 24 hours) exhibited
a greater than two-fold expression increase. Raf1 did not
show an over two-fold significant increase in expression;
however, it did show around a 1.5-fold expression increase
(6 and 24 hours) (Table 1).
To verify the microarray data, RT-PCR was performed for
the genes listed in Table 1. Table 2 compares the data
generated by microarray analysis and RT-PCR on genes in
the Erk pathway. Microarray and RT-PCR analyses showed
similar trends of increased expression of Erk pathway genes
in TGF-b1–treated NMuMG cells. However, the increased
H-ras expression after 24 hours of TGF-b1 treatment was not
confirmed by RT-PCR. Raf1 expression had a greater than
two-fold increase by RT-PCR at 1 hour, but did not have
increased expression by microarray analysis.
Activation of the Erk Signaling Pathway Was Required for
TGF-1–Induced EMT In Vitro
Results from microarray and RT-PCR analyses sug-
gested that in NMuMG cells, the Erk signaling pathway
may be activated by TGF-b1. Therefore, we investigated
further the relationship between the Erk pathway and TGF-
b1 signaling. The role of Erk activation in TGF-b1–induced
EMT is unclear. To test whether Erk signaling was necessary
for TGF-b1–induced EMT, Erk signaling was blocked using
the MEK1/2 inhibitor, U0126. TGF-b1 induced EMT in
NMuMG and MCT cells after 24 and 48 hours of TGF-b1
treatment, respectively (Figure 1). In the absence of treat-
ment, NMuMG and MCT cells had an epithelial-like morphol-
ogy with ZO-1, E-cadherin, and F-actin arranged in a cortical
pattern at cell–cell junctions (Figure 1). Upon TGF-b1 treat-
ment, phase contrast microscopy revealed that the cells
underwent a morphologic change, from a cobblestone-like
cell morphology to an elongated morphology. Immuno-
fluorescence microscopy showed that the epithelial mark-
ers ZO-1 and E-cadherin disappeared from cell – cell
junctions, and F-actin stress fibers formed after TGF-b1
treatment.
When NMuMG and MCT cells were treated with TGF-b1
in combination with the MEK1/2 inhibitor U0126 (TGF-b1 +
U0126), the morphologic change induced by TGF-b1 alone
was significantly blocked (Figure 1). The cobblestone-like
appearance and junctional localization of ZO-1 and E-cad-
herin in the cells treated with TGF-b1 + U0126 remained
intact. F-actin stress fiber formation was also attenuated
in the cells treated with TGF-b1 + U0126. Treatment with
U0126 alone did not change the morphology nor the local-
ization of E-cadherin, ZO-1 and F-actin in the NMuMG and
MCT cells. These data suggest that Erk signaling is neces-
sary for TGF-b1–induced EMT in NMuMG and MCT cells.
TGF-1 Increased Erk Phosphorylation in NMuMG
and MCT
In Figure 2, the effects of U0126 on the activation of the
Erk signaling pathway in NMuMG cells by TGF-b1 were
studied by immunoblotting with total Raf1, phospho-MEK1/
2, total MEK1/2, phospho-Erk1, and total Erk1 antibodies.
Total Raf1 and phospho-Erk1 protein levels increased in
NMuMG cells upon TGF-b1 treatment for 24 hours; however,
these increases were blocked by cotreatment with U0126.
Likewise, in MCT cells, phospho-Erk1 increased by TGF-b1
Figure 2. U0126 blocks TGF-1– induced phosphorylation of Erk. NMuMG
(A) and MCT (B) cells were incubated with TGF-1 (4 ng/ml) in the presence
or absence of 10 M U0126 for 24 hours. Cell lysates were analysed by
SDS-PAGE and immunoblotted with antibodies to phospho-Raf, total Raf,
phospho-MEK, total MEK, phospho-Erk, total Erk, phospho-Smad2, and
total Smad2. 1-Actin was used as a control for equal protein loading.
TGF-1 treatment increased levels of phospho-Erk, and U0126 abolished
this increase.
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treatment, and this increase was abolished by U0126. Phos-
pho-Smad2 protein levels increased after TGF-b1 treatment,
and this increase was not blocked by U0126, indicating that
U0126 did not inhibit TGF-b1 signaling through Smads. No
changes were observed in phospho-Raf, phospho-MEK,
total MEK, total Erk, or total Smad2 protein levels (Figure
2). b-Actin was used as control for equal protein loading.
MEK1/2 Inhibition Blocked TGF-1–Induced Erk1 Activity
To assess Erk1 activity, Erk1 kinase assays were per-
formed on cell lysates from NMuMG and MCT cells treated
with TGF-b1 and/or U0126 for 24 hours (Figure 3). In both
cell lines, TGF-b1 treatment induced Erk1 activity, whereas
cotreatment with U0126 blocked the TGF-b1–mediated in-
crease in Erk1 kinase activity. U0126 alone slightly de-
creased Erk1 activity. No kinase activity was detected in
the rabbit IgG immunoprecipitation control. Immunoblotting
with total Erk1 was used as a control for equal protein input in
the immunoprecipitations.
Discussion
cDNA microarray analyses demonstrated an over two-fold
increase in H-ras, N-ras, MEK2, and Erk1 gene expression
in TGF-b1–treated NMuMG cells. RT-PCR confirmed most
of these TGF-b1–induced gene expression changes. How-
ever, RT-PCR analyses did not confirm TGF-b1–induced
changes in H-ras or Raf1 expression. The algorithms used
to obtain the fold expression changes in RT-PCR and
microarray analyses were not the same; therefore, the
Figure 3. U0126 blocks Erk kinase activity induced by TGF-1. Erk kinase
assays were performed on NMuMG and MCT cells treated with TGF-1 (4
ng/ml) and/or U0126 (10 M) for 24 hours. Nontreated cells were used as a
control. Soluble lysates were immunoprecipitated with Erk1 antibody or rabbit
IgG (Rab. IgG) as a control. The immunoprecipitates were subjected to
immune complex kinase assays with myelin basic protein as the substrate.
The kinase reactions or immunoprecipitates were analyzed by phosphor-
imaging and immunoblotting with Erk1. NMuMG and MCT cells treated with
TGF-1 had enhanced Erk activation. Treatment with U0126 reduced Erk
kinase activity induced by TGF-1.
Figure 4. Model of TGF-1– induced Erk activation and EMT being blocked by U0126. TGF-1 may activate the Erk pathway through upstream factors, such as
Ras/Raf, or directly through more downstream factors, such as MEK or Erk. To investigate the role of Erk signaling in TGF-1–mediated EMT, the MEK1/2
inhibitor, U0126, was used to block Erk phosphorylation in NMuMG and MCT cells. In these cells, TGF-1 induction of Erk activity and EMT was blocked by U0126.
However, TGF-1 may activate other pathways, such as p38, JNK, PI3-kinase, and RhoA, to induce EMT in other cell types.
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fold changes observed between RT-PCR and microarray
may not be identical. However, the patterns of expression
determined by the two techniques were comparable.
Expression profiling at the mRNA level can provide im-
portant clues to the early changes in gene expression taking
place in physiological or pathologic processes. Most geno-
typic changes are fundamentally manifest through changes
in protein expression. Confirmation at the protein level was
carried out after the microarray studies because protein
expression levels are often not tightly correlated with RNA
expression. As we determined subsequently, not all of the
genes in the Erk pathway that exhibited upregulation at the
RNA level in microarray analyses demonstrated an upregu-
lation at the protein level.
The MEK1/2 inhibitor, U0126, was used to test whether
the Erk signaling pathway was functionally involved in
TGF-b1–induced EMT responses in NMuMG cells. Cultured
mouse proximal tubular cells (MCT), which undergo TGF-
b1–mediated EMT, were also used to determine if the Erk
pathway was important in TGF-b1–mediated EMT. The
fibroblast-like cell shape change induced by TGF-b1 was
significantly blocked by U0126 in both cell lines. This mor-
phologic change was accompanied by loss of ZO-1 and E-
cadherin at cell–cell junctions, and the formation of actin
stress fibers. After TGF-b1 plus U0126 treatment, NMuMG
cells retained more ZO-1 and E-cadherin at cell–cell junc-
tions than MCT cells. The inhibition of TGF-b1– induced
stress fiber formation by U0126 was more evident in MCT
cells than in NMuMG cells. Therefore, the importance of Erk
signaling in TGF-b1–induced stress fibers and ZO-1 and E-
cadherin redistribution may vary between cell lines. From
our data, we conclude that activation of the Erk signaling
pathway is required for TGF-b1–induced EMT in vitro.
However, Erk signaling may not be solely responsible for
TGF-b1–induced EMT because the blockage of EMT by
U0126 in NMuMG and MCT cells was not complete. Levels
of phosphorylated Smad2 increased after TGF-b1 treat-
ment and remained elevated after TGF-b1 plus U0126
treatment of NMuMG cells. Therefore, U0126 did not block
all TGF-b1 signaling and TGF-b1 may remain capable of
activating other signaling pathways, such as the p38
MAPK, PI3k/Akt, and RhoA GTPase pathways, to induce
EMT [8–10], as depicted in Figure 4.
The involvement of Erk signaling in TGF-b1– induced
EMT is controversial [17, 18]. However, our data show that
TGF-b1 may induce EMT in vitro through the activation of
Erk1 without the requirement for oncogenic Ras. Phosphor-
ylation of Raf1 was unaffected by treating NMuMG with
TGF-b1 and/or U0126. Total Raf1 protein levels increased
after TGF-b1 treatment but were unaffected by U0126. In-
terestingly, RT-PCR detected an upregulation of Raf1 gene
expression after TGF-b1 treatment. However, levels of
phosphorylated Erk1 and Erk1 kinase activity were in-
creased after TGF-b1 treatment and these increases were
blocked by U0126. Therefore, our data suggest that TGF-b1
may activate Erk1 to induce EMT in vitro.
Past reports have indicated that the ability of TGF-b1 to
induce EMT may depend on the transformation state of
the cell [18]. Many studies have shown a requirement for
overexpression/mutational activation of elements of Ras/
Raf/Erk for TGF-b1 –mediated EMT in human, rat, or mouse
epidermal, pancreas, intestine, liver, prostate, and mamma-
ry epithelial cells [10,17–26]. Constitutive activation of Ras
often leads to cellular transformation, and activation of
mutations in the ras oncogenes occurs in a high proportion
of human cancers [22,27–29]. Many carcinomas with acti-
vated ras oncogenes have undergone EMT [30–33]. In
contrast, our data show that the Erk pathway is activated
by TGF-b1 in two nontransformed cell lines NMuMG and
MCT that undergo EMT, in the absence of oncogenic
mutations in the Ras/Erk pathway; and that TGF-b1 activa-
tion of the Erk pathway is necessary for the induction of
EMT. The observation that U0126 blocks TGF-b–induced
Erk phosphorylation indicates that TGF-b activation of Erk is
MEK-dependent.
TGF-b1–induced EMT has been implicated in patholog-
ic states such as renal fibrosis and cancer. Our study is the
first report to show that TGF-b1 can induce EMT through
Erk activation in a cultured renal tubular cell line (MCT)
[34–37]. In addition, many epithelial solid tumors become
increasingly motile and invasive in response to TGF-b1.
Therefore, selective inhibition of the Ras/Erk pathway
may suppress TGF-b1–induced renal fibrosis and tumor
invasion.
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